{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:03:16Z","timestamp":1781211796401,"version":"3.54.1"},"reference-count":56,"publisher":"Impact Journals, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,2,16]]},"DOI":"10.18632\/oncotarget.6802","type":"journal-article","created":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T21:26:11Z","timestamp":1451597171000},"page":"7715-7731","source":"Crossref","is-referenced-by-count":71,"title":["Valproic acid potentiates the anticancer activity of capecitabine <i>in vitro<\/i> and <i>in vivo<\/i> in breast cancer models via induction of thymidine phosphorylase expression"],"prefix":"10.18632","volume":"7","author":[{"given":"Manuela","family":"Terranova-Barberio","sequence":"first","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Serena","family":"Roca","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Ilaria","family":"Zotti","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Leone","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bruzzese","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Vitagliano","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giosu\u00e8","family":"Scogliamiglio","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[{"name":"Institute of Protein Biochemistry, National Research Council, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Institute of Protein Biochemistry, National Research Council, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Franco","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Budillon","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Di Gennaro","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,12,31]]},"reference":[{"key":"1","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Jemal","year":"2015","journal-title":"CA"},{"key":"2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/17425255.2013.759939","article-title":"Pharmacokinetic evaluation of capecitabine in breast cancer","volume":"9","author":"De Luca","year":"2013","journal-title":"Expert opinion on drug metabolism & toxicology"},{"key":"3","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdp261","article-title":"Third consensus on medical treatment of metastatic breast cancer","volume":"20","author":"Possinger","year":"2009","journal-title":"Annals of oncology"},{"key":"4","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S1470-2045(14)70444-9","article-title":"Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial","volume":"15","author":"Mustacchi","year":"2014","journal-title":"Lancet Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Johnston","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/bjc.1995.392","article-title":"Increased sensitivity to the prodrug 5\u2032-deoxy-5-fluorouridine and modulation of 5-fluoro-2\u2032-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase","volume":"72","author":"Harris","year":"1995","journal-title":"Br J Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clbc.2012.10.002","article-title":"Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?","volume":"13","author":"Puglisi","year":"2013","journal-title":"Clinical breast cancer"},{"key":"8","first-page":"11619","article-title":"Immunolocalization of thymidylate synthase as a favorable prognostic marker in estrogen receptor-positive breast carcinoma","author":"Suzuki","year":"2015","journal-title":"Histology and histopathology"},{"key":"9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/157489207780832450","article-title":"Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents","volume":"2","author":"Caraglia","year":"2007","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Pazdur","year":"2007","journal-title":"The oncologist"},{"key":"11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/17474086.2013.814833","article-title":"Romidepsin for peripheral T-cell lymphoma","volume":"6","author":"Prince","year":"2013","journal-title":"Expert review of hematology"},{"key":"12","article-title":"FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma","author":"Dorff","year":"2015","journal-title":"Clin Cancer Res"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Panobinostat approved for multiple myeloma. Cancer discovery. 2015; 5:OF4.","DOI":"10.1158\/2159-8290.CD-NB2015-040"},{"key":"14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/epi.11.72","article-title":"Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance","volume":"3","author":"Munster","year":"2011","journal-title":"Epigenomics"},{"key":"15","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","article-title":"Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor","volume":"31","author":"Trepel","year":"2013","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4161\/cbt.8.9.8118","article-title":"Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed","volume":"8","author":"Budillon","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"17","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/1535-7163.MCT-09-0254","article-title":"Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis","volume":"8","author":"Budillon","year":"2009","journal-title":"Molecular cancer therapeutics"},{"key":"18","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/sj.bjc.6605969","article-title":"Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase","volume":"103","author":"Budillon","year":"2010","journal-title":"British journal of cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/jcp.22574","article-title":"HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT","volume":"226","author":"Budillon","year":"2011","journal-title":"J Cell Physiol"},{"key":"20","first-page":"2010","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","author":"Diederich","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"21","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","article-title":"Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study","volume":"25","author":"Sullivan","year":"2007","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","article-title":"Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial","volume":"97","author":"Jager","year":"2007","journal-title":"Br J Cancer"},{"key":"23","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1371\/journal.pone.0000098","article-title":"A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer","volume":"1","author":"Vela","year":"2006","journal-title":"PloS one"},{"key":"24","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","article-title":"Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC","volume":"15","author":"Sullivan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.24403","article-title":"Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells","volume":"125","author":"Ladner","year":"2009","journal-title":"Int J Cancer"},{"key":"26","first-page":"309","article-title":"Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines","volume":"26","author":"Damante","year":"2011","journal-title":"Oncol Rep"},{"key":"27","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Schreiber","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"28","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1535-7163.MCT-12-1242","article-title":"Histone deacetylase regulation of ATM-mediated DNA damage signaling","volume":"12","author":"Munster","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Mazitschek","year":"2010","journal-title":"Nature chemical biology"},{"key":"30","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-13-0626","article-title":"Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities","volume":"12","author":"Kral","year":"2013","journal-title":"Molecular cancer therapeutics"},{"key":"31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/cmdc.201300413","article-title":"Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next","volume":"9","author":"Mercurio","year":"2014","journal-title":"ChemMedChem"},{"key":"32","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Eda","year":"2012","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"e68915","DOI":"10.1371\/journal.pone.0068915","article-title":"Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma","volume":"8","author":"Eischen","year":"2013","journal-title":"PloS one"},{"key":"34","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bcp.2007.05.008","article-title":"Targeting platelet-derived endothelial cell growth factor\/thymidine phosphorylase for cancer therapy","volume":"74","author":"Balzarini","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"35","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1038\/cddis.2013.165","article-title":"Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells","volume":"4","author":"Budillon","year":"2013","journal-title":"Cell death & disease"},{"key":"36","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2011.11.142","article-title":"Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells","volume":"417","author":"He","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00280-007-0578-5","article-title":"Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity","volume":"62","author":"El Kouni","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"38","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ymgme.2004.12.004","article-title":"Thymidine phosphorylase gene mutations in patients with mitochondrial neurogastrointestinal encephalomyopathy syndrome","volume":"84","author":"Joly","year":"2005","journal-title":"Molecular genetics and metabolism"},{"key":"39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1471-2407-13-215","article-title":"Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression","volume":"13","author":"Denkert","year":"2013","journal-title":"BMC cancer"},{"key":"40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/mc.20373","article-title":"HDAC3 overexpression and colon cancer cell proliferation and differentiation","volume":"47","author":"Giardina","year":"2008","journal-title":"Molecular carcinogenesis"},{"key":"41","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2013.231","article-title":"Histone deacetylase 3 as a novel therapeutic target in multiple myeloma","volume":"28","author":"Haggarty","year":"2014","journal-title":"Leukemia"},{"key":"42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.vph.2014.01.003","article-title":"Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network","volume":"60","author":"Willems","year":"2014","journal-title":"Vascular pharmacology"},{"key":"43","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.bjc.6600808","article-title":"Role of platelet-derived endothelial cell growth factor\/thymidine phosphorylase in fluoropyrimidine sensitivity","volume":"88","author":"Peters","year":"2003","journal-title":"Br J Cancer"},{"key":"44","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Danenberg","year":"2000","journal-title":"Clin Cancer Res"},{"key":"45","first-page":"2948","article-title":"X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts","volume":"5","author":"Ishitsuka","year":"1999","journal-title":"Clin Cancer Res"},{"key":"46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<127::AID-IJC22>3.0.CO;2-6","article-title":"Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5\u2032-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models","volume":"83","author":"Tanaka","year":"1999","journal-title":"Int J Cancer"},{"key":"47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10549-011-1756-z","article-title":"Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5\u2032-DFUR, the bioactive metabolite of Xeloda","volume":"133","author":"Jean-Claude","year":"2012","journal-title":"Breast cancer research and treatment"},{"key":"48","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdn165","article-title":"Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer","volume":"19","author":"Veronesi","year":"2008","journal-title":"Annals of oncology"},{"key":"49","first-page":"e1","article-title":"Looking for predictive markers in breast cancer","volume":"16","author":"Puglisi","year":"2015","journal-title":"Lancet Oncol"},{"key":"50","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/jco.2015.33.15_suppl.1031","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Cortes","year":"2015","journal-title":"J Clin Oncol"},{"key":"51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10549-015-3633-7","article-title":"Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial","volume":"154","author":"Velikova","year":"2015","journal-title":"Breast cancer research and treatment"},{"key":"52","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1159\/000369487","article-title":"Quality of life under capecitabine (Xeloda(R)) in patients with metastatic breast cancer: data from a german non-interventional surveillance study","volume":"37","author":"Zaiss","year":"2014","journal-title":"Oncology research and treatment"},{"key":"53","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1186\/1471-2407-14-875","article-title":"Phase 1\/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial)","volume":"14","author":"Bianco","year":"2014","journal-title":"BMC cancer"},{"key":"54","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/1078-0432.CCR-05-1671","article-title":"Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo","volume":"12","author":"Budillon","year":"2006","journal-title":"Clin Cancer Res"},{"key":"55","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1038\/cddis.2013.406","article-title":"Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways","volume":"4","author":"Caraglia","year":"2013","journal-title":"Cell death & disease"},{"key":"56","first-page":"824","article-title":"Establishment of genetically diverse patient-derived xenografts of colorectal cancer","volume":"4","author":"MacKeigan","year":"2014","journal-title":"American journal of cancer research"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T15:53:40Z","timestamp":1594828420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,31]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,2,16]]}},"alternative-id":["6802","26735339"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.6802","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,31]]}}}